TDTeyfik Demir

Teyfik Demir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Teyfik Demir has a total of 200 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prognostic and clinicopathologic significance of the tumor–stroma ratio in pure endometrial serous carcinoma

    by Teyfik Demir, Zafer Kiraz, Canan Çolak, Ayşe Rumeysa Aydoğan Demir, Melih Akpunar, Güzin Demirağ, Mehmet Kefeli

  • Meme Cerrahisi

    by Büşra Ekici, Esra Özen Engin, Değercan Yeşilyurt, Nebile Çamaş, Muzaffer Önder Öner, Teyfik Demir, Murat Emre Reis, Osman Akdoğan, Abdül Rıdvan Kulu, Zeynep Betül Yıldız, et al.

  • Open Access

    Prognostic significance of folate receptor alpha expression in endometrial serous carcinoma: implications for patient stratification and targeted therapy

    by Teyfik Demir, Seda Nur Okur, Ayşe Rumeysa Aydoğan Demir, Güzin Demirağ, Mehmet Kefeli

    Objective: To evaluate the clinical significance of folate receptor alpha (FRα) expression in endometrial serous carcinoma. Methods: We retrospectively analyzed 47 patients with histopathologically confirmed endometrial serous carcinoma who underwent hysterectomy and received systemic therapy. FRα expression was assessed by immunohistochemistry and categorized as high or low based on ≥ 25% of tumor cells showing moderate-to-strong membranous staining. Associations with clinicopathological variables and survival outcomes were evaluated. Results: High FRα expression was observed in 29.8% of cases and was not associated with clinicopathological variables. Patients with high FRα expression had significantly shorter progression-free survival compared with those with low expression (median, 14 vs. 54 months; p = 0.007). In multivariable Cox regression analysis for PFS, high FRα expression remained independently associated with shorter PFS (HR 3.91, 95% CI 1.54–9.94, p = 0.004). No statistically significant difference in overall survival was observed ( p = 0.08). Conclusion: High FRα expression was associated with shorter progression-free survival in endometrial serous carcinoma. These findings suggest that FRα expression may represent a biologically relevant marker associated with disease progression and support further investigation in molecularly characterized cohorts.

  • Penile metastasis from rectal cancer: a case report

    by Canan Çolak, Teyfik Demir, Recep Türkel, Deniz Bayçelebi, Guzin Demirağ

    Penile metastasis is extremely rare despite the rich vascularization of the organ. The majority of metastatic lesions originate from adjacent genitourinary and pelvic organs, particularly the bladder, prostate, and rectosigmoid colon (28.6%, 27.9%, and 12.2%, respectively). In addition, penile metastasis from other systemic malignancies has also been reported. Because the number of published cases in the literature is limited, each new case contributes to a better understanding of the diagnosis and management strategies of penile metastases

  • Open Access

    Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

    by Mustafa Seyyar, Ali Kalem, Mürsel Sali, Berkan Karabuğa, Taha Koray Sahin, Ahmet Kürşad Dişli, Alper Türkel, Berkan Karadurmuş, Ece Şahin Hafızoğlu, Nilüfer Avcı, et al.

    Germline BRCA1/2-mutated (gBRCAm) hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) is a biologically distinct subset in which the efficacy of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors remains incompletely characterized. We evaluated real-world outcomes and prognostic factors in a multicenter retrospective Turkish cohort treated with a CDK4/6 inhibitor plus endocrine therapy (June 2020–September 2025). Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier and Cox methods. Among 121 patients, 30 (24.8%) had BRCA1, 88 (72.7%) had BRCA2, and three (2.5%) had dual mutations; 66.9% received first-line therapy, with ribociclib in 69.4% and palbociclib in 29.8%. Objective response rate was 69.4% and the clinical benefit rate was 82.6%. Median PFS was 17.0 months and OS 47.0 months. PFS was numerically longer in BRCA1 than in BRCA2 carriers (25.0 vs. 14.0 months), although the difference was not statistically significant in the pairwise comparison (HR 1.50, 95% CI 0.88–2.56; log-rank p = 0.135); the dual BRCA1/2 subgroup (n = 3) had the poorest outcomes and was assessed descriptively. OS did not differ significantly between BRCA1 and BRCA2 carriers (57.0 vs. 49.0 months; log-rank p = 0.520). PFS did not differ between ribociclib and palbociclib (p = 0.192); OS favored ribociclib at borderline significance (p = 0.050), but this was not confirmed in Cox regression. In multivariable analysis, ECOG ≥ 1 (HR 1.85; p = 0.010) and fulvestrant-based therapy (HR 1.74; p = 0.041) predicted shorter PFS; fulvestrant also predicted worse OS (HR 2.39; p = 0.008). CDK4/6 inhibitor-based therapy shows meaningful activity in gBRCAm HR+/HER2- MBC; the numerically poorer outcomes observed in BRCA2 carriers are hypothesis-generating and warrant validation in larger cohorts.

  • Open Access

    First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis

    by Mustafa Seyyar, Pervin Can Şancı, Abdullah Sakin, Ayberk Bayramgil, Özgecan Dülgar Kaya, Erdem Sünger, Özgür Açıkgöz, Teyfik Demir, Recep Türkel, Bahiddin Yılmaz, et al.

    Background and Objectives: Perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) is the standard of care for resectable gastric and gastroesophageal junction adenocarcinoma; however, up to 50% of patients develop metastatic recurrence. These patients have prior exposure to platinum and taxane agents, and optimal first-line treatment in the metastatic setting remains undefined. This study aimed to characterize real-world treatment patterns and outcomes in patients progressing after perioperative FLOT, focusing on relapse timing and HER2 status. Materials and Methods: This retrospective, multicenter cohort study included 296 patients from 31 centers across Türkiye, stratified into early relapse (≤6 months, n = 114) and late relapse (>6 months, n = 182) groups. Survival analyses were performed using the Kaplan-Meier method and Cox proportional hazards regression. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Results: Median PFS and OS for the entire cohort were 6 and 9 months, respectively. Early relapsers had significantly shorter median PFS (4 vs. 6 months, p = 0.029) and OS (8 vs. 12 months, p = 0.047); however, early relapse timing did not retain independent prognostic significance on multivariable analysis. No significant difference in PFS or OS was observed between cytotoxic chemotherapy regimens in either relapse group. HER2 positivity was the only independent predictor of improved PFS on multivariable Cox analysis (HR 0.48, 95% CI 0.29–0.81; p = 0.006). In the late relapse group, trastuzumab-based chemotherapy achieved a median PFS of 14 months and OS of 18 months, significantly superior to all cytotoxic regimens (PFS p = 0.007; OS p = 0.029). Conclusions: In patients progressing after perioperative FLOT, cytotoxic chemotherapy regimen selection did not demonstrate a statistically significant survival difference in this retrospective cohort, regardless of relapse timing. HER2 positivity is the dominant predictive biomarker, and trastuzumab-based therapy suggests a potential survival benefit that warrants prospective validation. Comprehensive biomarker profiling at metastatic diagnosis and prospective trials designed for this post-FLOT population are needed to establish evidence-based treatment standards.


  • Open Access

    Prognostic and Predictive Significance of Claudin-6 Expression in Advanced-Stage High-Grade Serous Ovarian Carcinoma

    by Teyfik Demir, Mehmet Kefeli, Ayşe Rumeysa Aydoğan Demir, Fatma Nur Uygun, Melih Akpunar, Elif Tekce Yıldız, Güzin Demirağ

    Background/Objectives: Claudin-6 (CLDN6) is an oncofetal tight junction protein that has recently emerged as a promising therapeutic target in various solid tumors. Despite this potential, the clinical significance of CLDN6 expression in advanced-stage high-grade serous ovarian carcinoma (HGSC)—specifically its role in platinum resistance—remains poorly understood. Methods: This retrospective study analyzed 119 patients with newly diagnosed FIGO stage III–IV HGSC who received platinum-based chemotherapy at a single tertiary center between 2015 and 2025. CLDN6 expression was evaluated via immunohistochemistry (IHC) on formalin-fixed paraffin-embedded (FFPE) tumor samples. High CLDN6 expression was defined as moderate-to-strong membranous staining in ≥50% of tumor cells. Clinicopathologic associations were assessed using chi-square tests, while logistic regression analysis identified predictors of platinum resistance. Finally, overall survival (OS) and progression-free survival (PFS) were evaluated using Kaplan–Meier methods and Cox proportional hazards models. Results: High CLDN6 expression was observed in 31 patients (26%). CLDN6 expression was not significantly associated with age, CA-125 level, lymph node metastasis, distant metastasis, surgical approach, or residual disease status. However, high CLDN6 expression was significantly associated with platinum resistance (61.3% vs. 28.4%, p = 0.001). In multivariable logistic regression analysis, residual disease (OR = 10.12, p > 0.001), high CLDN6 expression (OR = 4.52, p = 0.008), and elevated CA-125 levels (OR = 0.64, p = 0.041) were independently associated with platinum resistance. Median OS for the entire cohort was 43.8 months. High CLDN6 expression was associated with shorter OS (38.0 vs. 45.7 months, p = 0.042) and remained an independent predictor of mortality in multivariable Cox analysis (HR = 1.90, p = 0.026). CLDN6 expression showed a trend toward shorter PFS but did not reach statistical significance (p = 0.096). Conclusions: High CLDN6 expression is associated with platinum resistance and inferior overall survival in patients with advanced-stage HGSC. These findings suggest that CLDN6 may serve as a clinically relevant biomarker for chemoresistance and tumor aggressiveness. In the context of emerging CLDN6-targeted therapies, routine assessment of CLDN6 expression may facilitate the development of biomarker-driven therapeutic strategies for advanced ovarian cancer.


  • Open Access

    Prognostic and Predictive Significance of Claudin-6 Expression in Advanced-Stage High-Grade Serous Ovarian Carcinoma

    by Teyfik Demir, Mehmet Kefeli, Ayşe Rumeysa Aydoğan Demir, Fatma Nur Uygun, Melih Akpunar, Elif Tekce Yıldız, Güzin Demirağ

    Background: Claudin-6 (CLDN6) is an oncofetal tight junction protein that has recently emerged as a promising therapeutic target in various solid tumors. Despite this potential, the clinical significance of CLDN6 expression in advanced-stage high-grade serous ovarian carcinoma (HGSC)—specifically its role in platinum resistance—remains poorly understood. Methods: This retrospective study analyzed 119 patients with newly diagnosed FIGO stage III–IV HGSC who received platinum-based chemotherapy at a single tertiary center between 2015 and 2025. CLDN6 expression was evaluated via immunohistochemistry (IHC) on formalin-fixed paraffin-embedded (FFPE) tumor samples. High CLDN6 expression was defined as moderate-to-strong membranous staining in ≥50% of tumor cells. Clinicopathologic associations were assessed using chi-square tests, while logistic regression analysis identified predictors of platinum resistance. Finally, overall survival (OS) and progression-free survival (PFS) were evaluated using Kaplan–Meier methods and Cox proportional hazards models. Results: High CLDN6 expression was observed in 31 patients (26%). CLDN6 expression was not significantly associated with age, CA-125 level, lymph node metastasis, distant metastasis, surgical approach, or residual disease status. However, high CLDN6 expression was significantly associated with platinum resistance (61.3% vs 28.4%, p = 0.001). In multivariable logistic regression analysis, residual disease (OR = 10.12, p> 0.001), high CLDN6 expression (OR = 4.52, p = 0.008), and elevated CA-125 levels (OR = 0.64, p = 0.041) were independently associated with platinum resistance. Median OS for the entire cohort was 43.8 months. High CLDN6 expression was associated with shorter OS (38.0 vs 45.7 months, p = 0.042) and remained an independent predictor of mortality in multivariable Cox analysis (HR = 1.90, p = 0.026). CLDN6 expression showed a trend toward shorter PFS but did not reach statistical significance (p = 0.096). Conclusions: High CLDN6 expression is associated with platinum resistance and inferior overall survival in patients with advanced-stage HGSC. These findings suggest that CLDN6 may serve as a clinically relevant biomarker for chemoresistance and tumor aggressiveness. In the context of emerging CLDN6-targeted therapies, routine assessment of CLDN6 expression may facilitate the development of biomarker-driven therapeutic strategies for advanced ovarian cancer.


  • Meme Kanserinde Lokorejyonel Rekürrens Yönetimi

    by Teyfik Demir

    Meme kanseri, kadınlarda en yaygın görülen kanser türüdür ve tedavi sonrası lokal ve rejyonel nüks riski önemli bir sorun teşkil etmektedir. Lokal rekürrens, hastalığın aynı taraf memede ve göğüs duvarında tekrarıdır; rejyonel rekürrens ise kritik lenf nodlarındaki yeniden hastalığı ifade eder. Lokal nüks riski, pozitif cerrahi sınır, genç yaş, büyük tümör boyutu ve lenfovasküler invazyon gibi faktörlerle artmaktadır. Tanısal değerlendirme, görüntüleme ve biyopsi yöntemleriyle nüksün doğrulanmasını ve uzak metastazın dışlanmasını gerektirir. Tedavi yönetimi, hastanın önceki tedavi öyküsüne ve nüksün özelliklerine göre değişiklik göstermektedir. Rejyonel rekürrens durumunda ise cerrahi öncelikli olarak düşünülmekte ve gerektiğinde radyoterapi eklenmektedir. Sonuç olarak, lokorejyonel rekürrens yönetimi multidisipliner bir yaklaşım gerektirmekte, tedavi stratejileri bireysel durumlar göz önünde bulundurularak belirlenmelidir. Başarı, cerrahi, radyoterapi ve sistemik tedavi entegrasyonuyla artırılmaktadır.